Promore Pharma
STOCKHOLM, SE / ACCESSWIRE / November 9, 2021 / Promore Pharma (STO:PROMO)(FRA:8T0)
Stockholm, November 9, 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announced today that the company has received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical phase II trial of ensereptide for skin scarring prevention.
The company announces today that a clinical trial permit has been obtained from the Medical Products Agency in Sweden and that the company's application for approval from the Ethical Review Authority has also been granted. PHSU05 is a Phase II pilot study with the aim of being able to evaluate ensereptide regarding (i) local tolerance, (ii) the application process of the experimental drug, and (iii) preliminary effect on scar prevention after experimentally induced wounds in healthy volunteers. Planned study start is Q1 2022 and results from the study are expected in the winter of 2022/2023.
"This is an important step in our long-term goal of developing a new product concept to prevent the occurrence of post-surgical and post-traumatic scars on the skin. These approvals are fully aligned with our operational plan in the ensereptide project ", says Jonas Ekblom, CEO of Promore Pharma.
Bolagets ensereptide-program fokuseras för närvarande på prevention av ärr i huden i samband med kirurgi eller trauma, men det finns även potential att utveckla produkten för andra medicinska applikationer som prevention av sammanväxning efter hand- och ryggradskirurgi.
The company's ensereptide program is currently focused on the prevention of scarring of the skin in connection with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of adhesions after surgeries in the hand or spine.
Scars develop after virtually all types of damage to the skin. Although scars can often be considered trivial, a large proportion of them can be disfiguring and aesthetically pleasing, and they can also create itching, stiffness, sleep problems, anxiety, depression and negatively affect activities of daily life.
The world market for products for the treatment of scars, including laser treatment, scar revision and self-care products, amounts to USD 25 billion with an annual growth of about 10%, according to independent estimates. Today, there are no prescription drugs for wound prevention.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
This information is information that Promore Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-09 11:38 CET.
Attachments
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/671849/Promore-Pharma-Receives-Permits-to-Start-a-Phase-II-Clinical-Trial-Regarding-Scar-Prevention
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Doha Tattoo Festival Announced as Ticket Sales Officially Open16.11.2025 12:45:00 CET | Press release
DOHA, QA / ACCESS Newswire / November 16, 2025 / Under the patronage of His Excellency Sheikh Khalifa bin Hamad bin Khalifa Al Thani, Minister of Interior and Commander of the Internal Security Force (Lekhwiya), the first edition of the Doha International Music and Marching Festival (Doha Tattoo) will be held from 16 to 20 December 2025 at Katara Cultural Village. A press conference held at Katara Cultural Village unveiled the line-up of participating bands and ticket details, attended by members of the Doha Tattoo organising committee and partner representatives. The Doha Tattoo will combine precision with musical artistry, showcasing performances by distinguished musical bands from seven countries: the United Kingdom, the United States of America, Turkia, Hashemite Kingdom of Jordan , the Sultanate of Oman, Kazakhstan, and the State of Qatar. The participating line-up includes the Irish Guards and the Royal Air Force Music Services from the United Kingdom, the United States Air Force
Pet-Food Revolution: Two New Global Surveys Reveal Growing Guardian Openness to Sustainable Diets for Dogs and Cats14.11.2025 15:05:00 CET | Press release
LONDON, UK / ACCESS Newswire / November 14, 2025 / Two pioneering studies published in the journal Animals have explored in depth how dog and cat guardians perceive more sustainable pet food options. Led by Jenny L. Mace, Alexander Bauer, Andrew Knight and Billy Nicholles, the research sheds new light on the potential for alternative proteins and plant-based diets in the companion animal sector. Study 1 - Dogs: ‘Consumer Acceptance of Sustainable Dog Diets: A Survey of 2,639 Dog Guardians' In the first study, the team surveyed 2,639 dog guardians worldwide. Around 84% of respondents were currently feeding their dogs either conventional or raw meat-based diets. However, a substantial 43% of this group reported they would nevertheless consider at least one type of more sustainable dog food (such as vegan, vegetarian or cultivated-meat formulations). Among the alternative options, the most acceptable was cultivated meat-based dog food (chosen by 24% of these respondents), compared to vege
Kraft Heinz and OMP Showcase Smarter, More Sustainable Value Chain at Gartner Supply Chain Planning Summit13.11.2025 15:00:00 CET | Press release
ATLANTA, GEORGIA / ACCESS Newswire / November 13, 2025 / OMP, a leader in supply chain planning solutions, is showcasing how Kraft Heinz is transforming its global food supply chain at the Gartner Supply Chain Planning Summit 2025 in Denver. The leading food and beverage company will share how it is driving efficiency from farm to table with OMP's Unison Planning™. By leveraging autonomous planning, decision intelligence, and AI optimization, Kraft Heinz enhances collaboration, manages complexity, and reduces waste. Kraft Heinz's journey to a smarter, more sustainable value chain Thiago Serra, Head of Integrated Business Planning at Kraft Heinz, will discuss how smart, data-driven planning is helping the company build a more agile and sustainable value chain. Gain insights into how Kraft Heinz combines digital intelligence and end-to-end visibility to create real business impact across operations. Explore human-AI synergy at the OMP booth The Gartner Supply Chain Planning Summit, takin
Preservica Integrates Active Digital Preservation with Microsoft 365 Archive12.11.2025 15:00:00 CET | Press release
BOSTON, MA AND OXFORD, UK / ACCESS Newswire / November 12, 2025 / Preservica is expanding its ongoing collaboration with Microsoft with a new integration to bring embedded Active Digital Preservation™ to Microsoft 365 Archive. The latest Preserve365® integration offers Microsoft customers additional flexibility and control over the management of long-term SharePoint content. With Preservica's embedded Active Digital Preservation software, IT and Information Governance (IG) teams can now seamlessly archive and actively preserve high-value SharePoint sites - such as completed projects containing long-term regulatory, legal, or operational data. This protects critical data from obsolescence, ensuring long-term records are always immediately accessible in trusted, readable formats to enable business teams to respond quickly and confidently to audits, legal proceedings, maintenance continuity and AI-driven initiatives. Better together: Optimizing cost and compliance for long-term content. M
Karbon-X and Hockey Canada Partner to Make Sustainability Part of Canada's Game12.11.2025 15:00:00 CET | Press release
The Canadian-based climate-solutions company joins forces with Hockey Canada to deliver measurable sustainability impact across national tournaments and community programs. CALGARY, AB / ACCESS Newswire / November 12, 2025 / Following Hockey Canada's announcement earlier this week, Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is proud to confirm its new partnership with Hockey Canada, becoming the organization's Official Sustainability Partner and advancing verified sustainability initiatives across one of the nation's most celebrated sports. The multi-year partnership integrates verified, measurable sustainability programs into Hockey Canada's national tournaments and grassroots registration, empowering players, fans, and communities across the country to take part in meaningful environmental initiatives. Together, the two organizations are uniting national pride with environmental purpose, showing that every game can leave a positive impact. Through the partnership, sele
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom